Latest news

Search
Categories
News archive

Nanologica rekryterar Chief Scientific Officer

19 August, 2021

Nanologica har rekryterat Gary Pitcairn som Chief Scientific Officer som ett led i strategin att öka fokus på inhalation och respiratoriska sjukdomar, samt för att accelerera utvecklingen av bolagets teknologiplattform för inhalation, NLAB Spiro®. Nanologica utforskar nya möjligheter inom inhalation och respiratoriska sjukdomar och har rekryterat Gary Pitcairn som bolagets förste Chief Scientific Officer. Gary, som under 2021 varit en av Nanologicas vetenskapliga rådgivare inom inhalation, tillträder från och med den 23 augusti rollen som

Read more »

Interim Report Jan-Jun 2021 Nanologica AB (publ)

9 July, 2021

FINANCIAL SUMMARY Net sales for the quarter amounted to TSEK 4,497 (4,321) and for the half-year to TSEK 10,119 (7,975) The operating result for the quarter amounted to -8,094 TSEK (-4,097) and for the half-year to -14,862 TSEK (-10,129) Result after tax for the quarter amounted to -9,216 TSEK (-4,168) and for the half-year to -17,061 TSEK (-10,873) Earnings per share before and after dilution were SEK -0.33 (-0.18) for the second quarter and SEK

Read more »

Delårsrapport jan-jun 2021 Nanologica AB (publ)

9 July, 2021

FINANSIELL SAMMANFATTNING  Nettoomsättningen för andra kvartalet uppgick till 4 497 TSEK (4 321) och för halvåret till 10 119 TSEK (7 975) Rörelseresultatet för kvartalet uppgick till -8 094 TSEK (-4 097) och för halvåret till -14 862 TSEK (-10 129) Resultatet efter skatt för kvartalet uppgick till -9 216 TSEK (-4 168) och för halvåret till -17 061 TSEK (-10 873) Resultat per aktie före och efter utspädning var -0,33 SEK (-0,18) för kvartalet

Read more »

CEO Comment Second Quarter 2021

9 July, 2021

LARGE-SCALE PRODUCTION AND TOXICITY STUDIES Production of the company’s silica for preparative chromatography in large scale proceeds according to plan. Commercial material is expected to be delivered at the end of the year, after which the company can start delivering on customer agreements. At the same time, we continue to strengthen our platform in inhalation and respiratory diseases with a comprehensive tox program and increased resources for development and commercialization. Net sales for the second

Read more »

First Tox Study for Nanologica’s Inhalation Platform NLAB Spiro® Completed

8 July, 2021

Nanologica has completed the first study within the tox program for the inhalation platform NLAB Spiro®. The program now continues with further studies. NLAB Spiro® is Nanologica’s technology platform for inhalation. To validate the safety of the platform, toxicity studies are conducted in several steps and the first study has now been completed. Results from the sub-study are expected to be presented during the third quarter. During the second half of the year, the program

Read more »